Antibody Therapeutics Conference 2015

Infectious Diseases, Oncology, and Immunology

Friday, November 6

Venue: The First Conference Room, 2F, Center for Academic Activities, Academia Sinica

08:30 - 09:00 Registration

09:00 - 09:05 Dr. Chien-Jen Chen

Vice President, Academia Sinica, Taiwan

09:05 - 09:10 Dr. Andrew H.-J. Wang

Distinguished Research Fellow, Institute of Biological Chemistry, Academia Sinica,

Taiwan

President, Taiwan Antibody Association, Taiwan

Moderator: Dr. Andrew H.-J. Wang

Distinguished Research Fellow, Institute of Biological Chemistry, Academia Sinica,

Taiwan President, Taiwan Antibody Association, Taiwan

09:10 - 09:55 Dr. David Ho

Scientific Director and CEO, Aaron Diamond AIDS Research Center

Irene Diamond Professor, the Rockefeller University, New York, NY, USA

Engineering Bispecific Antibodies to Treat and Prevent HIV Infection

Moderator: Dr. Min-Liang Kuo

Dean and Professor, College of Life Science, National Taiwan University, Taiwan

10:00 - 10:35 Dr. Zhiqiang An

Director and Professor, Robert A. Welch Distinguished University Chair in Chemistry

Director, Texas Therapeutics Institute, the University of Texas Health Science

Center at Houston, USA

The Current Landscape of Monoclonal Antibody Drug Discovery

10:35 - 10:55 Tea break

Opening Remarks

Keynote

Session I: Perspectives on Current Trends and Future Opportunities

10:55 - 11:20 Dr. Lawrence L. Gan

President, Development Center for Biotechnology, Taiwan

Drug Delivery into the Brain – the Role of Transporters at the Blood Brain

Barrier and Convective Flows of Brain Interstitial Fluid (ISF) and

Cerebrospinal Fluid (CSF)

Moderator: Dr. Chia-Lin Jeff Wang

CEO, BioGate Medical Science Corp. Taiwan

11:25 – 12:00 Dr. Peter Kwong

Chief, Structural Biology Section and Structural Bioinformatics Core, Vaccine

Research Center, NIAID, National Institutes of Health, USA

HIV-1 Env as a Target of Neutralizing Antibodies

12:00 - 12:35 Dr. Robert Jordan

Sr. Research Fellow at Centocor, Janssen Division of Johnson & Johnson, USA

Visiting Professor, University of Texas Medical Center, Houston, USA

A Strategy to Overcome Protease-Mediated Inactivation of Iggs in Tumor

Environments

12:35 - 14:00 Lunch (Taiwan Antibody Association Members Meeting)

14:00 - 14:35 Dr. Arun Kashyap

Head of Research, Sea Lane Biotechnologies, USA

Surrobodies: A Novel Immune Scaffold for Immunotherapeutic Applications

Moderator: Dr. Fu-Tong Liu

Director and Distinguished Research Fellow, Institute for Biomedical Sciences,

Academia Sinica, Taiwan

14:40 - 15:15 Dr. Po-Jen Chen

Professor, Department of Medicine, Rheumatology Division, UCLA, USA

From Autoantibodies to Potentially Therapeutic Antibodies against HIV

15:15 - 15:50 Dr. Jeffrey J Molldrem

Session II: Emerging Targets

Session III: Translation and Development of Antibody Therapeutics

Professor and Chief, Section of Transplantation Immunology, Department of Stem

Cell Transplantation and Cellular Therapy, Division of Cancer Medicine,

University of Texas, MD Anderson Cancer Center, Houston, USA

T Cell Receptor-Like Antibody 8F4 Targets Leukemia and

Non-Hematopoietic Cancer

15:50 - 16:10 Tea break

16:10 - 16:35 Dr. Alice Yu

Distinguished Chair Professor and Co-Director, Institute of Stem Cell and

Translational Cancer Research, Chang Gung Memorial Hospital & Chang Gung

University, Taiwan

Development of Antibodies Directed against Cancer Associated Glycans

Moderator: Dr. Han-Chung Wu

Research Fellow and Deputy Director, Institute of Cellular and Organismic

Biology, Academia Sinica, Taiwan

16:40 - 17:05 Dr. An-Suei Yang

Research Fellow and Deputy Director, Genomics Research Center, Academia

Sinica, Taiwan

A High Throughput Antibody Engineering Platform for Discovering and

Optimizing Antibody-Drug Conjugates

17:05 - 17:30 Dr. Tien-Lu Cheng

Director of Graduate Institute of Medicine and Center for Biomarkers and Biotech

Drugs, Kaohsiung Medical University, Taiwan

Proteases (MMP2/9) Enhance the Affinity and Therapeutic Efficacy of

Targeted Antibody

17:30 - 18:05 Dr. Hao Chen

Director, BioProcess Development, Merck Research Laboratories, Kenilworth, NJ,

USA

Accelerated FIH (First-In-Human) for Mabs Enabled by Innovative

Bioprocess Strategy and Technologies

Session IV: Technologies for Antibody Discovery and Engineering

18:05 - 18:10 Dr. Fu-Tong Liu

Director and Distinguished Research Fellow, Institute for Biomedical Sciences,

Academia Sinica, Taiwan

18:10 Dinner & Taiwan Antibody Association Council Meeting (By Invitation)

Closing Remarks

Chairman

Dr. Andrew H.-J. Wang Academia Sinica

Committee

Dr. Fu-Tong Liu Academia Sinica

Dr. An-Suei Yang Academia Sinica

Dr. Zhiqiang An University of Texas Health Science Center at Houston, USA

Dr. Wei-Kuan Chi Development Center for Biotechnology

Taiwan Antibody Association

National Research Program for Biopharmaceuticals

Biochemical Technology Education Foundation

Academia Sinica

Institute of Biological Chemistry, Academia Sinica

Institute of Biomedical Sciences, Academia Sinica

Steering Committee

Organizers

Co-Organizers